- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03254836
Sleep and Survival in Colorectal Cancer
Sleep-wake Rhythm in the Perioperative Period in Patients Admitted for Elective Radical Surgery for Colorectal Cancer: an Observational Prospective Cohort Study.
Objective The objective of the current trial is to investigate the effect of perioperative sleep and circadian rhythm on the natural course of survival among patient diagnosed with colorectal cancer. Concurrently, outcome measures like depression, fatigue, quality of life, and co-morbidity will be measured continuously in the short-, intermediate- and long-term period following diagnosis.
The a-priori hypothesis is that preoperative sleep and circadian disturbances is a prognostic marker of reduced overall survival. Likewise, preoperative sleep-wake disturbances at baseline are expected to result in overall universally reduced quality of life, increased depression and fatigue. Furthermore, development of sleep-wake disturbances in the postoperative period as compared to preoperative sleep-wake rhythm is expected to a prognostic marker of negative outcomes.
Target and study population The study population are all patients diagnosed with colorectal cancer in Region Zealand recruited consecutively from the trial initiation until study end each patient with an intended 5 year follow-up period. All available cases will be included in the trial.
Study design The study will be an observational prospective cohort study applying a longituditional repeated measure design.
Exposures and outcomes of interest The primary outcomes in the trial are sleep and circadian outcomes measured via actigraphy in the perioperative period.
Furthermore, cancer related survival and overall survival in the 5 year follow-up period is considered primary outcomes.
Secondary outcomes consist of consecutively measured depression, fatigue, quality of life, follow-up treatment and co-morbidity.
Exposure variables are primary related to the cancer, i.e. cancer stage, surgical treatment, oncological treatment, baseline co-morbidity and pharmacological treatment. Some of the secondary outcomes could be expected to serve as confounding or mediating factors.
Meaningful control for confounding will in the analysis phase be cancer stage and baseline sleep-wake rhythm status.
Sampling methods All available cases will be sought included in the trial. No formal sample size has been performed and continues inclusion into the trial will be performed during an 1,5 year period.
Statistical analyses The relationship between overall survival and baseline sleep-wake rhythm will be investigated using survival statistics and/or multivariate logistic regression.
Expected results The investigators expect to see a marked difference in overall survival among patients with sleep and circadian disturbances at baseline.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
Zealand
-
Roskilde, Zealand, Danemark, 4000
- Department of Surgery, Zealand University Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Diagnosis of colorectal cancer as determined at the multi-disciplinary team conference.
- Admitted to elective radical surgery at the department of surgery at Zealand University Hospital
- Age above 18 years
- Informed consent
Exclusion Criteria:
- Non-ability to complete the study as assessed by the investigator
- Non-fluent in Danish.
- History of cognitive impairment (e.g. dementia)
- Paralysis or inability to answer study questioners electronically.
- Stadium 4 colonic adenocarcinoma with no surgical treatment options as determined at the multi-disciplinary conference.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Colorectal cancer undergoing elective surgery
All patients eligible for elective curative intended surgery for colonic adenocarcinoma at Zealand University Hospital. Patients will recieve treatment as per standard of care. |
Elective radical surgery for adenocarcinoma.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Actigraphy
Délai: Approximately 1 week preoperatively to 2 weeks postoperatively
|
Assessment of activity using accelerometor - Sleep and circadian assesment.
|
Approximately 1 week preoperatively to 2 weeks postoperatively
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Major Depression Inventory
Délai: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Assesment of depression
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
|
Insomnia Severity Index
Délai: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Subjective sleep assesment
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
|
Quality of life assesment
Délai: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
EORCT-QLQ-C30
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
|
Quality of life assesment
Délai: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
EORCT-QLQ-CR29
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
|
Mortality
Délai: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Baseline registration and follow-up assessments
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
|
Co-morbidity
Délai: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Baseline registration and follow-up assessments
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
|
Drug prescription history (Drug name and dosage)
Délai: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Baseline registration and follow-up assessments
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
|
Follow-up cancer treatment (Adjuvant chemotherapy, timing and duration)
Délai: Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Baseline registration and follow-up assessments
|
Baseline (approx. 1 week preoperatively), 2 weeks postoperatively, 3 months postoperatively, 6 months postoperatively, 12 months postoperativly, 24 months postoperatively, 36 months postoperatively, 60 months postoperatively.
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Michael T Madsen, M.D., Department of Surgery, Zealand University Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Symptômes comportementaux
- Les troubles mentaux
- Maladies du système digestif
- Maladies du système nerveux
- Tumeurs
- Dyssomnies
- Tumeurs par site
- Manifestations neurologiques
- Tumeurs gastro-intestinales
- Tumeurs du système digestif
- Maladies gastro-intestinales
- Maladies du côlon
- Maladies intestinales
- Maladies professionnelles
- Tumeurs intestinales
- Maladies rectales
- Troubles de la chronobiologie
- La dépression
- Troubles du sommeil et de l'éveil
- Tumeurs colorectales
- Troubles du sommeil, rythme circadien
Autres numéros d'identification d'étude
- MTM-V3
- SJ-600 (Autre identifiant: Region Zealand ethics Comittee)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Standard of care
-
Compedica IncProfessional Education and Research InstituteComplétéUlcère du pied diabétiqueÉtats-Unis, Canada
-
University of CalgaryHealth CanadaComplété
-
ULURU Inc.Navy Advanced Medical Development (NAMD) CommandRecrutementBlessures et BlessuresÉtats-Unis
-
RapidPulse, IncComplétéAVC ischémique aiguDanemark, Lettonie, Turquie, Brésil, Espagne
-
University Health Network, TorontoAnemia Institute for Research & EducationComplétéCardiopathie | CoagulopathieCanada
-
University Hospital Southampton NHS Foundation...University of Southampton; South Central Ambulance service; Hampshire and Isle...RecrutementCrise cardiaque | Réanimation cardiopulmonaire | Arrêt cardiaque hors de l'hôpitalRoyaume-Uni
-
University of Southern CaliforniaRecrutement
-
Medtronic Cardiac Rhythm and Heart FailureRésiliéInsuffisance cardiaque congestiveÉtats-Unis
-
University of StellenboschComplété
-
HeNan Sincere Biotech Co., LtdInconnue